FDA drug development initiative
FDA's initiative to accelerate development of new drugs will be a topic of the agency's Science Board meeting on April 22. The "Critical Path" initiative will redirect research funding towards identifying major barriers to drug development (1"The Pink Sheet" March 22, 2004, p. 30)...
You may also be interested in...
FDA's "Critical Path" initiative will redirect the agency's research funding towards identifying and alleviating some major barriers to drug development
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.